MedTrace Logo

A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

NCT00382239 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2015-02-23

No results posted yet for this study

Summary

This study will examine the response of several doses of LY2148568 (exenatide) and assess the effect on glucose control and safety and tolerability in Japanese patients with type 2 diabetes.

Conditions

Interventions

DRUG

exenatide (LY2148568)

subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks

DRUG

exenatide (LY2148568)

subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks

DRUG

exenatide (LY2148568)

subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks

DRUG

Placebo

subcutaneous injection twice daily, 0.02 mL to 0.04 mL

Sponsors & Collaborators

Principal Investigators

  • James Malone, MD · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-05-31
Completion
2007-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00382239 on ClinicalTrials.gov